The CFO discussed the rationale behind the second half of 2024 guidance, focusing on sustainable growth and margin expansion. The decision to pursue CMS coverage for DTD was driven by positive patient benefits despite not meeting primary endpoints. Cost savings from the DTD program will be reallocated to high-value initiatives.